Search results
Showing 1 to 3 of 3 results for cabotegravir
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
In development [GID-TA11304] Expected publication date: TBC
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Awaiting development [GID-TA10604] Expected publication date: TBC